Foundation Medicine, Inc. Sustainability Profile
Foundation Medicine, Inc., a leader in precision medicine, is headquartered in the United States and operates extensively across North America and Europe. Founded in 2010, the company has made significant strides in the oncology sector, focusing on genomic profiling to guide cancer treatment decisions. Foundation Medicine is renowned for its comprehensive genomic profiling services, including FoundationOne CDx and FoundationOne Liquid, which analyse tumour DNA to identify actionable mutations. These innovative products empower healthcare providers to tailor therapies to individual patients, setting the company apart in the competitive landscape of cancer diagnostics. With a strong market position, Foundation Medicine has achieved notable milestones, including partnerships with major pharmaceutical companies and integration into clinical practice guidelines, solidifying its reputation as a trusted resource in the fight against cancer.
DitchCarbon Score
How does Foundation Medicine, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Foundation Medicine, Inc.'s score of 82 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Foundation Medicine, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Roche Holding AG, which may influence its climate commitments and reporting practices. As part of its corporate family, Foundation Medicine may align its climate initiatives with those of Roche Holding AG. However, no specific reduction targets or climate pledges have been disclosed for Foundation Medicine itself. The absence of documented reduction initiatives suggests that the company is still in the process of establishing its own climate strategy or may rely on the overarching commitments of its parent company. Foundation Medicine's climate commitments and emissions data are therefore inherited from Roche Holding AG, which operates at a higher cascade level. This relationship may provide a framework for future emissions reporting and reduction targets, but specific details remain unspecified at this time.
How Carbon Intensive is Foundation Medicine, Inc.'s Industry?
How Carbon Intensive is Foundation Medicine, Inc.'s Location?
Foundation Medicine, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Foundation Medicine, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
